References
This section lists all references used for this website. References are divided into three, alphabetized sections: Journal Articles, Websites, and Figures/Images.
Journal Articles
 Garcia, A, S Burke, J Toner, et al. "Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks." Eur Heart J. 10 (2006): 1-6.
Grube, E, L Buellesfeld, et al. "Everolimus for stent-based intracoronary applications." Rev Cardiovasc Med 5 (2004): 3-8.
Heublein, B, R Rohde, and V Kaese, et al. "Biocorrosion of Magnesium Alloys: a New Principle in Cardiovascular Implant Technology?" Heart 89 (2003): 651-6.
Holmes D, M Leon, J Moses, et al. "Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis". Circulation 109 (2004):634-640.
Tsuji, T, H Tamai, K Igak, et ali. "Biodegradable stents as a platform to drug loading." Int J Cardiovasc Intervent 5 (2003): 13-6.
Vogt, F, A Stein, G Rettemeier, et al. "Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent." Eur Heart J. 25 (2004): 1330-40.
Websites
"Abbott's XIENCE V Drug-eluting Coronary Stent Superior to TAXUS Stent in Spirit II Clinical Trial". Abbott Laboratories. http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0345.htm.
"Circulation Article Reports that Medtronic's Endeavor Drug-Eluting Stent Provides Further Evidence of Effective, Safe, and Sustained Clinical Outcomes". Angioplasty.org. http://www.ptca.org/pr_medtronic/20060821.html.
"CYPHER Stent: A Remarkable Advance in Coronary Care". Johnson & Johnson. http://www.cypherusa.com.
"Drug-Eluting Stents". Angioplasty.org. http://www.ptca.org/stent.
"Future of the Coronary Stent Market: Who Will Win and Why?" Massachusetts Institute of Technology. http://ocw.mit.edu/NR/rdonlyres/Sloan-School-of-Management/15- 912Spring-2005/3AA0ACA0-6D1F-4B76-8955-E5ED85293EA7/0/drug_el_s_te_stt.pdf.
"Stent Procedure". American Heart Association. http://www.americanheart.org/presenter.jhtml?identifier=4721.
"TAXUS Drug-Eluting Coronary Stent System". Boston Scientific. http://www.taxus-stent.com/.
Figures / Images
Introduction (Figure 1):
Landholt. http://www.landholt.com/graphics/images/stent_03.jpg.
Clinical Background (Figures 2 and 3):
"Coronary Artery Disease". Sahajanand Medical Technologies Pvt Ltd. http://www.smtpl.com/diseases.html.
EBSCO Publishing. http://services.epnet.com/GetImage.aspx/getImage.aspx?ImageIID=6346.
MedicineNet. http://images.medicinenet.com/images/illustrations/balloon_angio.jpg.
Kershaw, Cutter, Ratinoff, LLP. http://www.stentinjury.com/clip_image002.jpg.
Current Devices (Figure 4):
"Photos & Graphics". Angiotech. http://www.angiotech.com/news/photos-graphics/.
Johnson & Johnson. http://www.jnj.com.
Boston Scientific. http://www.bostonscientific.com.
Medtronic. http://www.medtronic.com.
Abbott Laboratories. http://www.abbott.com.
|
